jazz
-
Spine
Implanet granted regulatory clearance in the USA (510k) and Europe (CE) for the Jazz Claw
Bordeaux, Boston, May 23, 2016 – IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible; OTCQX: IMPZY), a medical technology company specializing in…
Read More » -
Financial
Q1 2016 revenues Strong increase in U.S. JAZZ sales: +106%
BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News: IMPLANET (Paris:IMPL) (OTCQX:IMPZY) (Euronext: IMPL, FR0010458729, PEA-PME eligible; OTCQX: IMPZY), a medical technology company specializing in…
Read More » -
Spine
Implanet granted regulatory clearance in the U.S. (510k) and Europe (CE) for its new JAZZ Lock® implant
Bordeaux, Boston, 5 April 2016 – IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and…
Read More » -
Spine
Implanet Stands out at the North American Spine Society (NASS) Annual Meeting and Signs Six New Distribution Agreements
BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News: IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and…
Read More » -
Spine
Implanet Presents the Clinical Results of its JAZZ Implant in Adolescent Scoliosis Surgery
IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible) (Paris:IMPL), a medical technology company specializing in vertebral and knee-surgery implants, today announces the…
Read More »